The Immunocore share price is currently $38.50 per share. Immunocore is a clinical-stage biotechnology company developing proprietary, next-generation T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune diseases.
The biotech company Immunocore has seen its share price skyrocket in recent months, as investors bet on the success of its cutting-edge immunotherapy treatments. The company is currently developing treatments for a range of cancers and other diseases, and its technology has been praised by experts as being potentially groundbreaking. With so much potential, it’s no wonder that investors are eager to get in on the action.
However, with the stock price now trading at around $20 per share, some question whether the company is overvalued. Only time will tell if Immunocore can live up to the hype and deliver on its promises, but for now, its share price looks like it could continue to climb higher.
Immunocore Holdings
Immunocore is a clinical-stage immuno-oncology company developing first-in-class biological drugs called ImmTacs that harness the power of the body’s immune system to selectively target and kill cancer cells. Based on its proprietary technology, Immunocore has built a pipeline of ImmTac molecules in development against a broad range of solid tumors and blood cancers. The Company’s lead program, tebentafusp (IMCgp100), is in Phase III clinical trials for metastatic uveal melanoma, with data expected in 2020, and Phase II clinical trials for first-line treatment of non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and bladder cancer.
Founded in 2008, Immunocore is headquartered at Milton Park near Oxford, UK, with offices in Rockville, Maryland in the US. The Company has around 200 employees. In December 2018, Immunocore closed an oversubscribed $320 million Series B financing round led by new investor Baillie Gifford.
Existing investors also participated including Wellcome Trust Sanger Institute; IP Group; Malin Corporation; GlaxoSmithKline plc.; Microsoft co-founder Bill Gates through Cascade Investment LLC; Temasek Holdings Private Limited; Abingworth LLP; Hercules Capital Management LP; Woodford Patient Capital Trust plc.
Credit: seekingalpha.com
Is Immunocore Publicly Traded?
No, Immunocore is not publicly traded. It is a privately held company with headquarters in Oxfordshire, United Kingdom. The company was founded in 2008 and focuses on the development of T cell receptor-based therapeutics for the treatment of cancer, infectious diseases and autoimmune conditions.
Why Did Immunocore Stock Drop?
The Immunocore stock drop can be attributed to a number of reasons. First and foremost, the company has been embroiled in a number of lawsuits lately. This has led to increased scrutiny from investors and analysts alike.
Secondly, the company has been slow to commercialize its products. This has led to some investors losing faith in the company’s ability to generate revenue. Finally, the recent outbreak of coronavirus (COVID-19) has caused widespread panic and economic uncertainty.
This has made investors more risk-averse, leading them to sell off their shares of Immunocore.
🔴 Immunocore Holdings PLC-ADR IMCR Stock Trading Facts 🔴
Conclusion
The Immunocore share price is up today after the company announced that its experimental treatment for a rare form of cancer had shown positive results in early clinical trials. The stock is trading higher by over 5% in early morning trading. The company’s immunotherapy treatment, which is designed to treat solid tumors, was tested on patients with a rare form of gastrointestinal cancer known as GIST.
The study found that the treatment was able to shrink tumors in some patients and stabilize the disease in others. This is encouraging news for Immunocore, which has been working on this particular therapy for several years. While the data from this small study will need to be confirmed in larger trials, it provides hope that the company’s technology could one day be used to treat a range of different cancers.
